Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Castle Biosciences, Inc.
< Previous
1
2
3
4
Next >
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
November 08, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
September 25, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Host Second Annual Castle Cares Charity Walk
July 18, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
May 26, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
May 22, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
May 15, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports First Quarter 2023 Results
May 03, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies
May 03, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
April 28, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
April 25, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
April 20, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
April 19, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study
March 18, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
March 14, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
March 10, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine
March 08, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
February 28, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
February 24, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors
February 22, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines
February 09, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
February 07, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
February 01, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
January 23, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
January 17, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
January 08, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
November 21, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
November 17, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
November 15, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
November 14, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Tickers
CSTL
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit